Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

recordati rare diseases - tocofersolan - cholestasis; vitamin e deficiency - vitamini - vedrop huwa indikat fl-defiċjenza ta ' vitamina-e minħabba l-malassorbazzjoni tad-diġestjoni fil-pazjenti pedjatriċi li jsofru minn cholestasis kronika konġenitali jew cholestasis kronika ereditarji, mit-twelid (fil-kelma newborns) sa 16 jew 18-il sena, skond ir-reġjun.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

genzyme europe bv - sevelamer hydrochloride - hyperphosphatemia; renal dialysis - il-prodotti terapewtiċi l-oħra kollha - il-karatteristika hija indikata għall-kontroll ta 'iperfosfatemija f'pazjenti adulti li qed jirċievu emodijalisi jew dijalisi peritoneali. sevelamer hydrochloride għandhom jiġu użati fil-kuntest ta ' multipli terapewtiċi approċċ, li jistgħu jinkludu supplimenti tal-kalċju, dihydroxy 1,25 vitamina d3 jew waħda minn tiegħu analogi biex tikkontrolla l-iżvilupp tal-marda ta ' l-għadam renali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - il-prodotti terapewtiċi l-oħra kollha - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

n.v. organon - colecalciferol, alendronic acid (as sodium trihydrate) - l-osteoporożi, il-menopawża - drogi għat-trattament ta 'mard tal-għadam - trattament ta 'osteoporożi ta' wara l-menopawsa f'pazjenti f'riskju ta 'insuffiċjenza ta' vitamina-d. adrovance inaqqas ir-riskju ta'ksur vertebrali u tal-ġenbejn.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

n.v. organon - alendronic acid, colecalciferol - l-osteoporożi, il-menopawża - drogi għat-trattament ta 'mard tal-għadam - trattament ta 'osteoporożi ta' wara l-menopawsa f'pazjenti f'riskju ta 'insuffiċjenza ta' vitamina-d. fosavance inaqqas ir-riskju ta'ksur vertebrali u tal-ġenbejn.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

n.v. organon - alendronic acid, colecalciferol - l-osteoporożi, il-menopawża - drogi għat-trattament ta 'mard tal-għadam - trattament ta 'osteoporożi ta' wara l-menopawsa f'pazjenti f'riskju ta 'insuffiċjenza ta' vitamina-d. vantavo inaqqas ir-riskju ta'ksur vertebrali u tal-ġenbejn. it-trattament ta'l-osteoporożi wara l-menopawsa f'pazjenti li mhux qed jirċievu l-vitamina d-supplimentazzjoni u li huma f'riskju ta ' vitamina d-insuffiċjenza. vantavo inaqqas ir-riskju ta'ksur vertebrali u tal-ġenbejn.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - sevelamer carbonate - hyperphosphatemia; renal dialysis - il-prodotti terapewtiċi l-oħra kollha - renvela huwa indikat għall-kontroll ta 'iperfosfatemija f'pazjenti adulti li qed jirċievu emodijalisi jew dijalisi peritoneali. renvela huwa wkoll indikat għall-kontroll ta'l-iperfosfatemija fil-pazjenti adulti b'mard kroniku tal-kliewi mhux fuq dijalisi mal-fosforu fis-serum ≥ 1. 78 mmol/l. renvela għandu jintuża fi ħdan kuntest ta ' metodu terapewtiku multiplu, li jistgħu jinkludu l-suppliment tal-kalċju, 1,25-dihydroxy vitamin d3 jew wieħed mill-analogi tiegħu biex jikkontrollaw l-iżvilupp tal-marda fl-għadam tal-kliewi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - drogi oħra tas-sistema nervuża - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, tromboċitopenika, idjopatika - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.